Sec Form 3 Filing - Meyers Steve Lawrence @ OCULAR THERAPEUTIX, INC - 2025-06-11

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Meyers Steve Lawrence 2. Issuer Name and Ticker or Trading Symbol OCULAR THERAPEUTIX, INC [ OCUL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Commercial Officer (Last) (First) (Middle) C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE 3. Date of Earliest Transaction (MM/DD/YY) 06/11/2025 (Street) BEDFORD, MA01730 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 152,728 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 5.22 ( 2 ) 04/03/2032 Common Stock 45,000 D Stock Option (Right to Buy) $ 3.88 ( 3 ) 01/29/2033 Common Stock 100,000 D Stock Option (Right to Buy) $ 5.18 ( 4 ) 02/02/2034 Common Stock 145,000 D Stock Option (Right to Buy) $ 7.44 ( 5 ) 02/10/2035 Common Stock 222,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Meyers Steve Lawrence C/O OCULAR THERAPEUTIX, INC. 15 CROSBY DRIVE BEDFORD, MA01730 Chief Commercial Officer Signatures /s/ Todd Anderman, Attorney-in-Fact for Steve Lawrence Meyers 06/23/2025 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Includes 11,111 restricted stock units ("RSUs") remaining unvested pursuant to an award of 33,333 RSUs granted under the 2021 Stock Incentive Plan, as amended (the "Plan"), of Ocular Therapeutix, Inc. (the "Corporation") on January 30, 2023; 32,206 RSUs remaining unvested pursuant to an award of 48,309 RSUs granted under the Plan on February 3, 2024; and 74,000 RSUs remaining unvested pursuant to an award of 74,000 RSUs granted under the Plan on February 11, 2025. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the respective date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. ( 2 )This option was granted on April 4, 2022 and vests over four years, with 1/4 of the shares underlying the option having vested on March 15, 2023 and 1/48 of the shares vesting monthly thereafter. ( 3 )This option was granted on January 30, 2023 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date. ( 4 )This option was granted on February 3, 2024 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date. ( 5 )This option was granted on February 11, 2025 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.

Remarks: Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.